RBI repo cut by 50 bps strong, timely policy shift: Experts
Managing Director and CEO of Indian Overseas Bank Ajay Kumar Srivastava said in a statement that the move indicates a strong and timely policy shift that aligns with balancing growth with price stability.
Kolkata, Jun 6 (PTI) Experts on Friday welcomed the decision of the Reserve Bank of India (RBI) to reduce the repo rate by 50 basis points to 5.50 per cent and cash reserve ratio (CRR) by 100 basis points in four tranches.
According to Srivastava, the decision in the CRR cut is expected to release Rs 2.5 lakh crore liquidity in the system, which will ease credit conditions in the banking sector.
Siddhartha Sanyal, chief economist of Bandhan Bank, said, 'The central bank sprang several surprises. The rate cut by 50 basis points came as a surprise as our expectations were 25 basis points. The larger than expected rate cut brings in more focus on the transmission of the monetary policy actions into the real economy.' Sakshi Gupta, principal economist of HDFC Bank, said that the RBI delivered a surprise monetary bonanza.
'This reflects the central bank's endeavour to spur aggregate demand in the face of global headwinds,' Gupta said.
'The RBI kept its growth forecast unchanged at 6.5 per cent while reducing inflation estimate to 3.7 per cent for the current financial year,' the economist said.
Chief investment officer of Axis Securities PMS, Naveen Kulkarni, said that the RBI's decision to cut rates by 50 basis points was a surprise.
'The decision of the central bank to cut rates by 50 basis points came as a surprise against our expectations. Softening inflation trends, expected to remain below the tolerance limit, will lead to demand recovery,' Kulkarni said. PTI dc SBN SBN
This report is auto-generated from PTI news service. ThePrint holds no responsibility for its content.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Economic Times
6 minutes ago
- Economic Times
Zydus Lifesciences shares in focus after USFDA nod for Celecoxib capsules
Zydus Lifesciences shares will be in focus after the company received final approval from the United States Food and Drug Administration (USFDA) for its Celecoxib capsules, a medication used for pain management. ADVERTISEMENT The approval covers Celecoxib capsules in strengths of 50 mg, 100 mg, 200 mg, and 400 mg, the company said in a regulatory filing on Tuesday. The drug will be manufactured at Zydus Lifesciences' facility in Ahmedabad. Celecoxib, sold under the brand name Celebrex, is a nonsteroidal anti-inflammatory drug (NSAID) used to treat pain and inflammation caused by conditions such as arthritis, ankylosing spondylitis, menstrual pain, and juvenile rheumatoid arthritis in children aged two years and above. According to IQVIA data, Celecoxib capsules recorded sales of $122.6 million in the US for the 12 months ending May this approval, Zydus now has 428 ANDA approvals and has filed a total of 492 since it began the process in June, the USFDA issued two observations following an inspection conducted between June 9 and 18 at the company's oncology injectable manufacturing facility at SEZ 1 near Matoda, Ahmedabad. ADVERTISEMENT According to Trendlyne, the average target price for Zydus Lifesciences shares stands at Rs 967, indicating a potential downside of 1% from current levels. Of the 30 analysts tracking the stock, most have maintained a 'Hold' rating. ADVERTISEMENT Zydus Lifesciences shares are down 19% over the past year but have gained 63% over the last two years. The company's current market capitalisation is Rs 97,317 crore. (Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of the Economic Times) ADVERTISEMENT (You can now subscribe to our ETMarkets WhatsApp channel)
Mint
7 minutes ago
- Mint
TCS to Ashok Leyland: 6 stocks in focus to trade ex-date for dividend or Bonus shares today
Dividend Stocks: TCS, Anant Raj, Avadh Sugar, TCI Express, and Ultramarine & Pigments are the five key companies in focus to trade ex-dividend today. Ashok Leyland, on the other hand, will trade the ex-date for a bonus. Issue of 1:1 These companies had decided that July 15, 2025, would be the record date for determining whether shareholders are eligible to receive dividends on bonus shares. To be included on the list of eligible shareholders to receive dividends under the T+1 settlement method, investors who wanted dividends or bonus shares had to buy shares at least one day before the record date. Tata Consultancy Services Ltd.— At the Board Meeting on July 10, the Directors declared an interim dividend of ₹ 11 per equity share having a face value of ₹ 1 in the Company. The interim dividend will be paid on Monday, August 4, 2025, to equity shareholders of the Company whose names appear on the Company's Register of Members or in the Depositories' records as beneficial owners of the shares as of Wednesday, July 16, 2025, the Record Date. Anant Raj Ltd— For the fiscal year 2024-25, the company would pay a final dividend of Rs. 0.73 per equity share (face value Rs. 2). Avadh Sugar & Energy Ltd—The company had recommended a final dividend of Rs. 10/- per equity share of 10/- each for the year ended March 31, 2025, which, however, is also subject to approval of the shareholders at the ensuing Annual General Meeting. TCI Express Ltd—A 100% final dividend of Rs. 2.00 per equity share had been recommended for the fiscal year ending March 31, 2025, subject to shareholder approval at the Company's 17th Annual General Meeting. Ultramarine & Pigments Ltd—The company had recommended the final dividend of Rs. 6 per share for the financial year ended 31st March, 2025, on equity shares of Rs. 2 each. The Board had approved issuing bonus equity shares in a 1:1 ratio, with one equity share of ₹ 1/- for every fully paid-up equity share of ₹ 1/- held by the Company's shareholders as of the Record Date. The Allotment Committee has set Wednesday, July 16, 2025, as the record date for identifying eligible shareholders for bonus shares. The deemed date of allotment will be Thursday, July 17, 2025. Disclaimer: The views and recommendations made above are those of individual analysts or brokerage companies and not of Mint. We advise investors to check with certified experts before making any investment decisions
Economic Times
7 minutes ago
- Economic Times
ICICI Lombard shares in focus after Q1 PAT rises 29% YoY. Should you buy, sell or hold?
ICICI Lombard General Insurance Company shares are expected to be in focus on Wednesday, July 16, after the company posted strong results for the first quarter of fiscal year 2026 (Q1 FY2026). The insurer reported a substantial 28.7% year-on-year (YoY) increase in profit after tax (PAT), reaching Rs 747 crore, compared to Rs 580 crore in Q1 FY2025. ADVERTISEMENT In terms of Gross Direct Premium Income (GDPI), ICICI Lombard posted modest growth of 0.6%, at Rs 7,735 crore in Q1 FY2026, up from Rs 7,688 crore a year earlier. This lags the general insurance industry's overall growth of 8.8%. However, excluding the impact of accounting changes, the company's GDPI recorded a more robust growth of 4.8%, compared to the industry's 12.8% rise. Profit before tax (PBT) for Q1 FY2026 grew 28.4% to Rs 994 crore, up from Rs 774 crore in the same period last year. Additionally, ICICI Lombard's capital gains rose to Rs 380 crore in Q1 FY2026, from Rs 284 crore in Q1 FY2025, further boosting its overall financial performance. The company's Return on Average Equity (ROAE) improved to 20.5% in Q1 FY2026, up from 19.1% in Q1 FY2025, reflecting more efficient use of shareholder capital. Its solvency ratio remained strong at 2.70x as of June 30, 2025, compared to 2.69x at the end of March 2025, well above the regulatory minimum of 1.50x. ADVERTISEMENT The combined ratio, a key metric of underwriting profitability, stood at 102.9% for Q1 FY2026, slightly higher than 102.3% in Q1 Tuesday, shares of ICICI Lombard closed nearly 1% lower at Rs 2,001.05 on BSE. ADVERTISEMENT Also read: Dolly Khanna bets on this smallcap stock with 1.5% stake purchase in June quarter After the Q1 results, here's what brokerages say: ADVERTISEMENT Nuvama has reiterated its Buy rating on ICICI Lombard while raising the target price to Rs 2,340 from Rs 2,300. The brokerage noted that heightened competitive intensity has impacted both the motor and group health segments. It has also trimmed its FY26E–FY28E adjusted PAT (APAT) estimates by 0.7% to 1.2%. However, Nuvama expects a recovery in motor insurance growth as volumes increase, which could support a rebound in overall Oswal (MOSL) also maintained its Buy call, revising the target price upwards to Rs 2,400. While the combined ratio slightly missed estimates, strong investment income supported PAT growth. MOSL noted early signs of industry recovery in FY26, which should aid ICICI Lombard's profitability. It expects the combined ratio to improve to 101.2% by FY27 and forecasts PAT growth of ~23% in FY26 and 15% in FY27. (Disclaimer: Recommendations, suggestions, views, and opinions given by the experts are their own. These do not represent the views of The Economic Times) (You can now subscribe to our ETMarkets WhatsApp channel)
